Cresar at a Glance
Cresar 40 mg Cipla is a pharmaceutical-grade telmisartan formulation developed by Cipla Pharmaceuticals for laboratory research applications. Telmisartan is an angiotensin II receptor blocker (ARB) that functions as a selective antagonist of the AT1 angiotensin receptor subtype. This compound demonstrates high affinity binding to AT1 receptors while exhibiting negligible interaction with AT2 receptors in molecular binding studies. The research-grade formulation provides investigators with standardised compound availability for examining cardiovascular pharmacology, receptor binding kinetics, and cellular signalling pathway mechanisms. Telmisartan’s unique pharmacological profile includes partial peroxisome proliferator-activated receptor gamma (PPARγ) agonist activity, distinguishing it from other angiotensin receptor antagonists in preclinical research models. Researchers at Stroid UK Shop frequently investigate this compound alongside other cardiovascular research tools available through our comprehensive catalogue.
Laboratory Applications
Research scientists examine Cresar 40 mg in various laboratory protocols investigating cardiovascular biology and receptor pharmacology. The compound serves as a valuable tool for studying renin-angiotensin-aldosterone system modulation in cell culture models and molecular binding assays. Investigators analyse telmisartan’s dual mechanism involving AT1 receptor antagonism combined with PPARγ partial agonism in metabolic research applications. Laboratory studies examine the compound’s effects on vascular smooth muscle cell proliferation, endothelial function markers, and inflammatory cytokine expression in controlled experimental conditions. Researchers often compare telmisartan’s binding characteristics with other compounds available in our telmisartan research collection. The pharmaceutical-grade formulation enables precise analytical work examining dose-response relationships and receptor selectivity profiles. Studies investigate the compound’s molecular interactions with various cellular targets, providing insights into cardiovascular pharmacology mechanisms relevant to broader research initiatives including those explored with selective androgen receptor modulators and bioactive peptides in multi-target research protocols.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Telmisartan |
| Strength | 40 mg per tablet |
| Manufacturer | Cipla Pharmaceuticals |
| CAS Number | 144701-48-4 |
| Molecular Formula | C₃₃H₃₀N₄O₂ |
| Molecular Weight | 514.62 g/mol |
| Storage Requirements | Room temperature, dry environment |
| Research Applications | Cardiovascular pharmacology, receptor binding studies |
Research Compliance
Cresar 40 mg Cipla is supplied exclusively for in-vitro laboratory research purposes and is not intended for human consumption, veterinary applications, or any form of clinical use. This research-grade telmisartan formulation is designed for qualified investigators conducting studies in controlled laboratory environments. Researchers must ensure proper handling procedures, appropriate storage conditions, and adherence to institutional research protocols when examining this compound. All experimental work should follow established laboratory safety guidelines and regulatory requirements for pharmaceutical research materials. This product is not for therapeutic use and has not been evaluated for human safety or efficacy outside of controlled research settings.
